EXPERIENCE OF HERCEPTIN APPLICATION IN TREATMENT OF PATIENTS WITH THE HER2 POSITIVE NEGLECTED FORMS OF BREAST CANCER

Application of the recombinant monoclonal antibody Herceptin in combination with a modern chemotherapy at patients with the neglected forms of HER2 positive breast cancer is not only pathogenetic, but also is instrumental grounded in the increase of general survivability and improvement of patient’s quality of life.